About the Event
Americans spend $134B each year seeking treatment for chronic back pain, the #1 cause of disability around the world. Yet current treatments provide little to no relief.
SpineThera has developed a sustained release, microsphere delivery platform technology that recently completed a Phase 1/2 clinical trial with excellent results:
- 69% of respondents reported a 50% or greater reduction in pain through 180 days
- The treatment was safe with side effects equivalent to a placebo saline injection
Join our webinar with SpineThera Founder and CEO, Jeff Missling, to hear more of the story, and how this platform technology applies to multiple high value applications beyond back pain.